Chargement en cours...
Disability outcome measures in therapeutic trials of relapsing-remitting multiple sclerosis: effects of heterogeneity of disease course in placebo cohorts
OBJECTIVES—Recent phase III clinical trials of immunomodulatory therapies in relapsing-remitting multiple sclerosis have shown significant benefits of active treatment on relapse related end points, but effects on disability outcomes have been inconsistent. These apparent discrepancies could be due...
Enregistré dans:
| Auteurs principaux: | , |
|---|---|
| Format: | Artigo |
| Langue: | Inglês |
| Publié: |
BMJ Group
2000
|
| Sujets: | |
| Accès en ligne: | https://ncbi.nlm.nih.gov/pmc/articles/PMC1736854/ https://ncbi.nlm.nih.gov/pubmed/10727480 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1136/jnnp.68.4.450 |
| Tags: |
Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!
|